Xeris Biopharma Holdings, Inc.
XERS
$7.59
$0.020.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.62% | 29.88% | 23.89% | 22.72% | 35.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.62% | 29.88% | 23.89% | 22.72% | 35.31% |
| Cost of Revenue | 47.96% | 35.13% | 28.58% | 27.62% | 20.91% |
| Gross Profit | 33.21% | 28.79% | 22.89% | 21.66% | 38.52% |
| SG&A Expenses | 9.26% | 8.05% | 7.73% | 13.80% | 10.55% |
| Depreciation & Amortization | 0.00% | -0.01% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.25% | 10.45% | 10.91% | 15.96% | 11.65% |
| Operating Income | 89.99% | 63.56% | 37.41% | 5.61% | 39.75% |
| Income Before Tax | 40.21% | 27.08% | 10.08% | -3.91% | 18.83% |
| Income Tax Expenses | -789.63% | -173.35% | -81.59% | -85.34% | 135.65% |
| Earnings from Continuing Operations | 46.28% | 30.01% | 11.92% | -2.13% | 16.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.28% | 30.01% | 11.92% | -2.13% | 16.62% |
| EBIT | 89.99% | 63.56% | 37.41% | 5.61% | 39.75% |
| EBITDA | 133.53% | 86.74% | 51.15% | 6.87% | 49.39% |
| EPS Basic | 49.57% | 35.13% | 16.87% | 2.64% | 19.41% |
| Normalized Basic EPS | 54.12% | 41.14% | 24.36% | 0.17% | 24.82% |
| EPS Diluted | 49.57% | 35.13% | 16.87% | 2.64% | 19.41% |
| Normalized Diluted EPS | 54.12% | 41.14% | 24.36% | 0.17% | 24.82% |
| Average Basic Shares Outstanding | 7.95% | 8.09% | 6.59% | 5.00% | 3.41% |
| Average Diluted Shares Outstanding | 7.95% | 8.09% | 6.59% | 5.00% | 3.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |